摘要
目的观察吡柔比星(THP)经动脉灌注化疗栓塞对原发性肝癌(HCC)的临床有效率及不良反应。方法采用Seldinger技术经股动脉插管,超选择性置管于靶动脉内。采用以THP为主的联合化疗方案,经动脉插管行灌注化疗栓塞,治疗间隔4～6周,共2～3个疗程。结果34例中无完全缓解(CR)病例,部分缓解(PR)25例,无变化(NC)5例,进展(PD)4例,总有效率达73.5%;甲胎蛋白(AFP)有20例明显下降,4例稳定,10例略升高;毒副反应为白细胞降低7例(20.6%),血小板减少4例(11.7%),恶心、呕吐15例(44.1%),心电图一过性ST段改变2例(5.8%),脱发1例(2.9%)。结论以THP为主的联合化疗栓塞方案治疗HCC疗效较好,毒副反应较低。
Objective To observe the clinical effect and adverse effect of THP in the treatment of liver cancer with transcatheter arterial embolization （TAE）. Methods All catheterization were performed via transfemoral approach by the Seldinger technique, TAE by using THP- based regimen were given after superselect into target artery. The interval between the courses of treatment was 4- 6 weeks and every patient received 2- 3 courses of project. The curative effect and side and toxic effect were observed. Results The total effective rate was 73.5% ; AFP decreased in 20 cases, increased in 10 cases; the toxic responses included 7 cases （20. 6% ） of leukopina, 4 cases （11.7%） of platelet thrombocytopenia, 15 cases （44. 1% ） of nausea and vomiting, 1 case （2. 9% ） of alopecia and 2 cases （5.8%） of temporary ST change in ECG. Conclusion The THP- based regimen has better curative effect and less side effect in treating HCC with TAE. THP is a highly effective, broad - spectrum and safe anti - tumor medicine.
出处
《中国药业》
CAS
2007年第17期44-45,共2页
China Pharmaceuticals
